Annual Awards Program Recognizes BostonGene’s Innovation in Advancing Cancer Care With AI-Driven, Blood-Based Immune System Profiling Platform
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that it has garnered the “Cancer Immunology Solution of the Year” award in the fourth annual BioTech Breakthrough Awards program. The awards, conducted by BioTech Breakthrough—a market intelligence organization recognizing standout life sciences and biotechnology companies—highlight top global innovations.
BostonGene’s immune system profiling platform predicts therapy responses in cancer patients using a single blood sample. Its proprietary technology combines flow cytometry with whole transcriptome sequencing to evaluate biomarkers, gene expression, cell states, cellular composition, and immunophenotypes. The AI-powered platform offers a minimally invasive, comprehensive overview of a patient’s immune system. Trained on 2,500 manually annotated flow cytometry samples and validated on independent cohorts, it identifies 650 immune cell types and activation states, correlating with manual annotation. The platform has analyzed over 18,000 blood samples from healthy donors and patients with infections, autoimmune conditions and cancers, identifying five conserved immunotypes—validated using RNA sequencing of peripheral blood lymphocytes. This immune system profiling platform enables biomarker identification, disease monitoring and treatment response assessment, supporting clinical decision-making and uncovering immune-related conditions. Published in the May 2024 issue of Cancer Cell, BostonGene’s study, “Comprehensive Peripheral Blood Immunoprofiling Reveals Five Immunotypes with Immunotherapy Response Characteristics in Patients with Cancer,” identifies five immunotypes conserved across diverse diagnoses.
“The immune system is heterogeneous and dynamic, requiring continuous monitoring for optimal treatment decision-making with cancer patients and immunotherapy options. As a fully adaptable model, our immune system profiling platform-defined immunotypes offer a strong foundation for patient selection in clinical trials and improved response rates,” said Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene. “We are grateful to BioTech Breakthrough for this accolade and remain committed to transforming cancer care through innovation and advancing precision oncology. Our goal is to equip clinicians with the solutions they need to improve patient outcomes and push the boundaries of cancer treatment.”
The annual BioTech Breakthrough Awards program evaluates top companies, solutions, and products in the global life sciences and biotechnology markets. This year’s program attracted thousands of nominations from across the globe, serving as a platform for recognizing bold ideas shaping biotechnology’s future.
“BostonGene is bringing precision medicine into daily clinical practice and empowering physicians to deliver personalized therapies for cancer patients. Immunotherapy has revolutionized cancer treatment, however, a biomarker-based approach is needed to ensure that only those most likely to benefit are treated. Currently, invasive tissue biopsies are often required to evaluate biomarkers but this painful and limiting procedure captures only a single time point,” said Bryan Vaughn, Managing Director, BioTech Breakthrough. “BostonGene’s blood-based immune system profiling platform eliminates this challenge, representing a significant step forward in optimizing immunotherapy and improving outcomes for patients. It’s a pleasure to recognize BostonGene with the ‘Cancer Immunology Solution of the Year’ award!”
About BostonGene Corporation
BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients’ molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit www.BostonGene.com.
About BioTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Immunology, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughAwards.com
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
Contacts
Media:
BostonGene
Erin Keleher
+1-617-283-2285
Erin.Keleher@bostongene.com
